We would love to hear your thoughts about our site and services, please take our survey here.
Hemcheck have distribution network across Europe and the States so a ready made outlet for Bio Vinos products
Early days but hopefully a good foundation
About Hemcheck
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
Logged out default avatar
Login Register
Monitor
Quote
Charts
Trades
News
Toplists
Alerts
Portfolio
Level 2
Free BB
PBB
Follow Feed
Crypto
Crypto Toplists
Top Exchanges
Top Defi Tokens
New Cryptos
Algorithms
Platforms
Cryptocurrency Converter
Crypto Trader Alerts
Crypto NewsWire
PlusOneCoin
World Markets
World
USA
United Kingdom
Europe
Australia
Brazil
Canada
France
Germany
Greece
Italy
Netherlands
Portugal
Forex
Live Forex Rates
Currency Converter
Forex News
Commodities
Financials
Share Financials
UK Screener
UK IPOs
Sector Sheet
Dividend Summary
Most Shorted Stocks
Large Fund Holdings
Sitemap
FTSE 100
London Stock Exchange
UK IPOs
Newsletters
ADVFN Newspaper
DDE
Data Downloads
Brokers
Subscriptions
ADVFN Logo
Copyright © 2023 ADVFN plc
Switch to Desktop View
Craven House Capital Share News - CRV
Current Price
$0.205
0.00 0.0%
Bid Price Offer Price
0.16 0.25
High Price Low Price Open Price
Shares Traded Last Trade Market Cap (m)
0.00 00:00:00 1
Craven House Capital PLC Investee company update: Bio Vitos
Intraday Craven House Capital Chart
Intraday Craven House Capital Chart
08/02/2023 7:00am
UK Regulatory (RNS & others)
TIDMCRV
RNS Number : 2316P
Craven House Capital PLC
08 February 2023
8 February 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018.
Craven House Capital plc
("Craven House" or the "Company")
Investee company update: Bio Vitos
The Board of Craven House notes the announcement released earlier today by Hemcheck Sweden AB ("Hemcheck") and is pleased to announce that its 24.5% owned investee compan y Bio Vitos has today entered into an agreement with Hemcheck , a company listed on the Nasdaq Stockholm (the "Agreement"). As part of the Agreement and subject to approval by Hemcheck's shareholders at an EGM to be convened at a date still to be confirmed, Hemcheck will create a new subsidiary ("NewCo") and transfer all current business and assets of Hemcheck to this new subsidiary. Under the terms of the Agreement, Bio Vitos has agreed to provide Hemcheck with SEK1.23 million in cash, within 14 days after the approval of the transaction by Hemcheck's shareholders.
Bio Vitos will then pay a further SEK4 million in cash, to Hemcheck, within thirty days following the distribution of shares in NewCo to Hemcheck shareholders.
In addition Bio Vitos has agreed to provide Hemcheck with its IP rights (patents or patent applications) in respect of an active substance Iron Succinate (Succifer and used in a marketed product Inofer). In exchange, Bio Vitos will receive 259,654,000 shares in Hemcheck, amounting to circa 88.3% of Hemcheck's share capital.
Craven House's holding in Bio Vitos will remain unchanged.
No not aware of any share distribution
Update from innomedical now available
Why No ? earn a fee on arranging a floatation when this is substantial then CICC can float
So. CIC Securitisation is 100 % owned by Stuart Bromley and CIC Capital will earn a fee for handling the floatations it would seem
all resolutions passed 20.3m votes received
Yes the 4th not the 2nd my typo
Yes l have all very positive but await the CIC FUND update due today
I thought the idea was to cash in the warrants when they were cheaper than the shares but this must be a new concept!
https://ir.lmfunding.com/press-releases/detail/50/lm-funding-announces-receipt-of-2-9-million-warrant
Unexpected $2.9million @ $2.40 raised from warrants I should say so !! Currently @$1.71
Intolsol which CICC has a client is up 68% today ???
OK Found the chat on CICG board
Hi
What we looking for nothing on BB ?
This is not quite the same but remote monitoring or communication at home for Bleepa ??
https://www.fool.com/investing/2020/04/03/fcc-approves-200-million-program-to-boost-teleheal.aspx
https://imagingendpoints.com/breakthrough-radiomic-technology-patent-issued-to-imaging-endpoint
Assume this news release has been posted which shows good progress for TexRad and noting that Imaging Endpoint are actively seeking partners to commercialize its technologies for routine patient care.
Imaging Endpoints is honored and excited to share with the market this patented technology that could provide patients and physicians the advantage of faster, less invasive information that is critical to treatment decisions and patient outcomes.
https://apnews.com/Newswire/e1d1b45508d25af88b3c21c4d01b7b10
Have you seen the latest financial statement
https://docs.wixstatic.com/ugd/a6bced_3b3ac87b6ec644238a2c56bbb4625bcd.pdf